China will refine its drug pricing system with 14 measures, Xinhua reports

China's initiative to refine its drug pricing system with a set of 14 measures signals a regulatory shift aimed at optimizing drug affordability and supply stability.

Newsquawk StaffPublished On the live feed at 9 more headlines followed before this page went public
Newsquawk headlinesUTC

BoE's Mann says concerned that a price shock could show up in wage expectations; inflation expectations are very volatile if CPI is above 3-3.5%

BMW (BMW GY) Q1 deliveries -3.5% Y/Y to 565,748 units

China will refine its drug pricing system with 14 measures, Xinhua reports

The ECB is urging EU governments to fast-track common deposit insurance to break the impasse in banking integration while warning against softening guardrails to boost competitiveness, the FT reports

Iranian President Pezeshkian says ready to continue talks with America within legal frameworks

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • The plan includes optimising launch pricing for innovative and newly listed drugs
  • Will use payment standards to guide pricing, encouraging reasonable pharmacy retail prices, strengthening supply and price stability for shortage medicines, and enhancing monitoring, enforcement, audit oversight and drug value assessment to keep prices within a reasonable range.
Context

This is significant for pharmaceutical companies as it aligns pricing strategies with government standards, potentially impacting margins and the market for both domestic and international firms operating in China.

Related headlines

The whole workspace, free to try.

Try it free